The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
SwainS, BaselgaJ, KimS, . Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med.2015;372():724-734.
2.
GianniL, PienkowskiT, ImY, . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol.2011;13(1):25-32.
3.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines – Breast Cancer V.3.2015. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed October 12, 2015.
GloverZW, GennaroL, YadavS, . Compatibility and stability of pertuzumab and trastuzumab admixtures in IV infusion bags for coadministration. J Pharm Sci.2013;102(3):794-812.
BaschE, PrestrudAA, HeskethPJ, . Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.2011;29(31):4189-4198.
